Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
McKesson
McKinsey
Medtronic
Johnson and Johnson

Last Updated: January 21, 2022

DrugPatentWatch Database Preview

Details for Patent: 7,276,250


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,276,250
Title:Sustained release formulations of oxymorphone
Abstract:Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.
Inventor(s): Baichwal; Anand R. (Wappingers Falls, NY), Kao; Huai-Hung (Syosset, NY), McCall; Troy W. (Germantown, TN)
Assignee: Penwest Pharmaceuticals Company (Danbury, CT)
Application Number:10/189,932
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,276,250
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery; Use; Dosage form;

Drugs Protected by US Patent 7,276,250

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-001 Jun 22, 2006 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y RELIEF OF MODERATE TO SEVERE PAIN ⤷  Try it Free
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-005 Feb 29, 2008 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y RELIEF OF MODERATE TO SEVERE PAIN ⤷  Try it Free
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-002 Jun 22, 2006 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y RELIEF OF MODERATE TO SEVERE PAIN ⤷  Try it Free
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-006 Feb 29, 2008 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y RELIEF OF MODERATE TO SEVERE PAIN ⤷  Try it Free
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-003 Jun 22, 2006 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y RELIEF OF MODERATE TO SEVERE PAIN ⤷  Try it Free
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-007 Feb 29, 2008 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y RELIEF OF MODERATE TO SEVERE PAIN ⤷  Try it Free
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021610-004 Jun 22, 2006 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y RELIEF OF MODERATE TO SEVERE PAIN ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,276,250

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 359077 ⤷  Try it Free
Austria 376832 ⤷  Try it Free
Australia 2002316582 ⤷  Try it Free
Australia 2002318211 ⤷  Try it Free
Australia 2002320309 ⤷  Try it Free
Brazil 0205721 ⤷  Try it Free
Brazil 0205722 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
AstraZeneca
Boehringer Ingelheim
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.